Proprietary human antibody discovery platform
ARTC-501/MAM01 Clin0 malaria; APN-497444 RD oncology; APN-346958 RD oncology; APN-122597 RD oncology
Atreca is developing technology to predict and produce therapeutic antibodies against specific antigens. Using their proprietary Immune Repertoire Capture® technology, Atreca identifies functional human antibodies from patients who have an anti-tumor immune response. The technology enables Atreca to accurately quantitate and analyze a patient's antibody repertoire using bioinformatics expertise and select antibody sequences that led to the anti-tumor response. Following selection, Atreca uses their industrialized wet lab infrastructure to interrogate the clinical candidate antibodies that selectively bind tumor tissue. Atreca is building a diverse portfolio to drive tumor-targeting in multiple indications.